Gene therapy in Alzheimer’s disease – potential for disease modification
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Introduction Targets and ongoing research Potential gene therapy target candidates Down‐regulation of AD‐associated proteins by siRNA Concluding remarks Alzheimer’s disease (AD) is the major cause of dementia in the elderly, leading to memory loss and cognitive decline. The mechanism underlying onset of the disease has not been fully elucidated. However, characteristic pathological manifestations include extracellular accumulation and aggregation of the amyloid β‐peptide (Aβ) into plaques and intracellular accumulation and aggregation of hyperphosphorylated tau, forming neurofibrillary tangles. Despite extensive research worldwide, no disease modifying treatment is yet available. In this review, we focus on gene therapy as a potential treatment for AD, and summarize recent work in the field, ranging from proof‐of‐concept studies in animal models to clinical trials. The multifactorial causes of AD offer a variety of possible targets for gene therapy, including two neurotrophic growth factors, nerve growth factor and brain‐derived neurotrophic factor, Aβ‐degrading enzymes, such as neprilysin, endothelin‐converting enzyme and cathepsin B, and AD associated apolipoprotein E. This review also discusses advantages and drawbacks of various rapidly developing virus‐mediated gene delivery techniques for gene therapy. Finally, approaches aiming at down‐regulating amyloid precursor protein (APP) and β‐site APP cleaving enzyme 1 levels by means of siRNA‐mediated knockdown are briefly summarized. Overall, the prospects appear hopeful that gene therapy has the potential to be a disease modifying treatment for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“For instance, retroviral vector-mediated gene delivery has been used for the treatment of metastatic melanoma and chronic granulomatous disease using gene-transferred T cells and blood stem cells, respectively [20, 21].”
MethodTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“These mutations affect BACE1 and -secretase cleavage, respectively, leading to an increase in both total A levels and in A 42/A 40 ratio, and induce an age-dependent accumulation of A from 3 months of age and a cognitive decline from 6 months of age [99, 100].”
BackgroundNeurotrophins as synaptic modulators
Poo, M.-M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35049004 · Cited by 1,775 · cited 2×
“In addition to its roles in neural growth and cell maintenance, NGF also influences synaptic functions [27, 28].”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“APOE is the genetic risk factor that is most strongly associated with susceptibility to AD (recently reviewed in [7, 137, 138]).”
BackgroundCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Decreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232 · cited 1×
“BDNF levels in AD The BDNF level in brain is decreased not only in AD [68–73], but also in PD [74], Huntington’s disease [75], depression [76, 77] and schizophrenia [78].”
BackgroundApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Cited by
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Alzheimer’s Disease, Inflammation, and the Role of Antioxidants
Sinyor, B., Mineo, J., & Ochner, C. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200171 · Cited by 120
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
“Gene therapy strategies can be targeted to brain endothelial cells at the BBB or directly to brain cells [169].”
BackgroundKunkle, B. W., Jaworski, J., Barral, S., Vardarajan, B., Beecham, G. W., Martin, E. R., Cantwell, L. S., Partch, A., Bird, T. D., Raskind, W. H., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.020 · Cited by 32
“Finally, it has been suggested that BDNF-based drugs might be effective therapies for AD and other neurodegenerative diseases [50], with targeting ofBCL11B interactionswith BDNFeven being suggested as a feasible therapeutic approach to elevate BDNF signaling in neurodegenerative drug development [40].”
Background
Metadata
- Authors
- Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B., & Saido, T. C.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 14
- Issue
- 4
- Pages
- 741-757
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2082185331
- Cited by
- 91
- References
- 37
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy in Alzheimer’s disease – potential for disease modification. https://app.cochat.ai/papers/10.1111/j.1582-4934.2010.01038.x
- The paper
- Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B., & Saido, T. C. (2010). Gene therapy in Alzheimer’s disease – potential for disease modification. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2010.01038.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.